Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zofin for Moderate to Severe COVID-19 ARDS
NCT04384445Phase 2Completed
- Sponsor
- Organicell Regenerative Medicine
- Start
- Sep 2020
- Primary completion
- Jul 2023
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of zofin in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Organicell Regenerative Medicine. Started Sep 2020; status: completed.
02
Drugs
zofin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04384445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384445.